BIP
EGRX

Brandes Investment Partners’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Brandes Investment Partners’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-745,080
Closed -$3.9M – 193
2023
Q4 		$3.9M Sell
745,080
-389,283
-34% -$3.84M 0.06% 118
2023
Q3 		$17.9M Buy
1,134,363
+293,276
+35% +$5.27M 0.35% 75
2023
Q2 		$16.4M Buy
841,087
+296,037
+54% +$7.02M 0.33% 77
2023
Q1 		$15.5M Buy
545,050
+128,873
+31% +$3.83M 0.33% 73
2022
Q4 		$12.2M Sell
416,177
-51,680
-11% -$1.64M 0.34% 59
2022
Q3 		$12.4M Buy
467,857
+3,565
+0.8% +$131K 0.32% 76
2022
Q2 		$20.6M Buy
464,292
+32,442
+8% +$1.49M 0.5% 54
2022
Q1 		$21.4M Sell
431,850
-182,515
-30% -$8.76M 0.46% 61
2021
Q4 		$31.3M Sell
614,365
-58,711
-9% -$3.04M 0.68% 48
2021
Q3 		$37.5M Sell
673,076
-43,797
-6% -$2.15M 0.81% 42
2021
Q2 		$30.7M Buy
716,873
+227,246
+46% +$9.38M 0.68% 48
2021
Q1 		$20.1M Buy
489,627
+225,230
+85% +$10.5M 0.48% 60
2020
Q4 		$12.3M Buy
264,397
+109,473
+71% +$5.12M 0.32% 73
2020
Q3 		$6.58M Buy
154,924
+147,833
+2,085% +$6.47M 0.23% 81
2020
Q2 		$340K Sell
7,091
-143,510
-95% -$7.16M 0.01% 146
2020
Q1 		$6.93M Buy
150,601
+145,413
+2,803% +$7.3M 0.24% 80
2019
Q4 		$312K Buy
5,188
+57
+1% +$3.4K 0.01% 126
2019
Q3 		$290K Sell
5,131
-2,262
-31% -$127K 0.01% 123
2019
Q2 		$412K Sell
7,393
-14,585
-66% -$761K 0.01% 117
2019
Q1 		$1.11M Buy
21,978
+668
+3% +$29.7K 0.03% 106
2018
Q4 		$858K Buy
21,310
+17,652
+483% +$910K 0.02% 117
2018
Q3 		$254K Sell
3,658
-8,327
-69% -$631K 0.01% 135
2018
Q2 		$907K Sell
11,985
-13,234
-52% -$833K 0.02% 111
2018
Q1 		$1.33M Buy
+25,219
New +$1.47M 0.03% 117

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.82% 1-Year Est. Return

Brandes Investment Partners's EGRX Position: Q1 2024 in Review

Brandes Investment Partners sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2024, closing a stake of 745,080 shares — an estimated $3.9M sold.

Brandes Investment Partners first reported a position in EGRX in Q1 2018 and held it in 24 quarters. The position peaked at $37.5M in Q3 2021. 91 funds tracked by Wall St. Rank hold EGRX as of Q1 2024.

  • Brandes Investment Partners reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
  • Brandes Investment Partners sold 745,080 Eagle Pharmaceuticals, Inc. shares in Q1 2024, an estimated $3.9M.
  • Brandes Investment Partners first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2018 and held it in 24 quarters.
  • Brandes Investment Partners's Eagle Pharmaceuticals, Inc. position peaked at $37.5M in Q3 2021.
  • 91 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2024.

Based on Brandes Investment Partners's 13F filing for Q1 2024, filed 15 May 2024.